Printer Friendly

EMPI RESPONDS TO STOCK ACTIVITY

 EMPI RESPONDS TO STOCK ACTIVITY
 ST. PAUL, Minn., March 23 /PRNewswire/ -- Empi, Inc. (NASDAQ: EMPI),


a medical device manufacturer, announced today that the company is not aware of any adverse developments which would account for the recent decline in the company's stock price.
 The company also reported that management is comfortable with the majority of analysts' earnings estimates for the first quarter, ending March 31, 1992, that are in the range of $.14 to $.17 per share.
 For the year ended Dec. 31, 1991, Empi reported record sales and net income. Sales rose to $21.8 million, up 36 percent from $16.0 million for 1990. Net income doubled to $2.0 million, or $.59 per share, up 126 percent from $903,000, or $.31 per share.
 Empi develops, manufactures and distributes non-invasive biomedical devices and accessories for electro-therapeutic applications in physical medicine, orthopedics, rehabilitation and neurological markets. The company's shares are traded on the NASDAQ national market system under the symbol EMPI.
 -0- 3/23/92
 /CONTACT: Timothy Briggs of Empi, 612-639-2330, or Marian Briggs or Diane Rose, both of Padilla Speer Beardsley Inc., 612-871-8877, for Empi/
 (EMPI) CO: Empi, Inc. ST: Minnesota IN: MTC SU:


KH -- MN007 -- 0618 03/23/92 13:34 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 23, 1992
Words:206
Previous Article:NORTRAN RESOURCES LTD. SIGNS INTERIM RESEARCH AGREEMENT
Next Article:ALDUS SHIPS UPDATE TO ALDUS FREEHAND FOR WINDOWS
Topics:


Related Articles
EMPI REPORTS RECORD RESULTS FOR SECOND QUARTER AND FIRST HALF
EMPI COMPLETES ACQUISITION OF BIOFEEDBACK COMPANY
EMPI REPORTS STRONG SALES AND EARNINGS GAINS FOR 1993 THIRD QUARTER
MEDAMICUS ANNOUNCES SIGNING OF INVESTMENT AGREEMENT WITH EMPI
EMPI FINALIZES INVESTMENT AND TEST MARKETING AGREEMENT FOR TWO INCONTINENCE PRODUCTS DEVELOPED BY MEDAMICUS, INC.
EMPI, MEDAMICUS UNABLE TO FINALIZE DISTRIBUTION AGREEMENT
EMPI REPORTS PROGRESS IN INCONTINENCE BUSINESS
EMPI, INC. ANNOUNCES PLAN TO REPURCHASE ADDITIONAL SHARES OF ITS COMMON STOCK
EMPI, INC. OBTAINS ADDITIONAL MARKETING RIGHTS; EXPANDS REHABILITATION PRODUCT LINES
Empi, Inc. Announces Plan To Continue Repurchasing Shares Of Its Common Stock

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters